Nivasorexant - Idorsia Pharmaceuticals
Alternative Names: ACT-539313; SORALatest Information Update: 05 Nov 2023
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals
- Class Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Binge-eating disorder
- Discontinued Anxiety disorders
Most Recent Events
- 10 May 2022 Adverse events data from a phase I trial in Binge-eating disorder released by Idorsia Pharmaceuticals
- 10 May 2022 Efficacy and adverse events data from a phase II trial in Binge-eating disorder released by Idorsia Pharmaceuticals
- 13 Apr 2022 Idorsia Pharmaceuticals completes a phase I trial in Healthy volunteers (Combination therapy) in Germany (PO) (NCT05254548)